BACARDI
5.7.2022 13:02:05 CEST | Business Wire | Press release
After decades spent pioneering sustainable practices, MARTINI, the world’s number one Italian sparkling wine and vermouth from family-owned Bacardi, has reached a sustainability milestone – 100% of the wineries for the entire MARTINI portfolio are now certified sustainable.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220705005231/en/
Every drop of grape juice used in the production of MARTINI vermouth and sparkling wines, including MARTINI Fiero and the new MARTINI Non-Alcoholic Aperitivo range, is now sourced from wineries certified according to the standard set by Equalitas, the most comprehensive sustainability standard in Italian wine making.
With the sugarcane for BACARDÍ® rum and the 10 botanicals for BOMBAY SAPPHIRE® already 100% sustainable sourced, this news is another major step towards Bacardi achieving its 2025 goal of sourcing 100% of its key ingredients from sustainably certified suppliers.
Established 160 years ago next year, MARTINI has long pioneered doing the right thing for the environment. In 1987, L'Osservatorio MARTINI – the MARTINI Observatory – was established in Northern Italy as a center dedicated to promoting sustainable farming methods, first for its wines and, more recently, the many botanical ingredients used to craft its iconic vermouths and non-alcoholic aperitivo range.
“It takes a lot of years and a lot of dedication to achieve a milestone like this one,” says MARTINI Master Blender Beppe Musso. “For generations, we have cared for the environment, for our suppliers and for their communities. This certification by Equalitas recognizes the value of those relationships and the value of pioneering sustainable practices.”
Stefano Stefanucci, Director of Equalitas, said: “The scale of what MARTINI has achieved is a first in the Italian wine industry. Equalitas certification is a rigorous process that doesn’t happen overnight so for MARTINI to achieve it across 100% of its wineries is extraordinary.”
Equalitas only works with third-party auditors who are experts with a deep knowledge of the wine sector and the certification process is wholly holistic. Equalitas embraces three sustainability pillars – environmental, ethical and economical – and takes into consideration everything from a winery’s carbon footprint and water consumption through to fair commercial terms for farmers and good social practices including training and welfare.
Victoria Morris, Global VP MARTINI, added: “The care we place on the sourcing of every ingredient is reflected in the quality and taste of every drop of MARTINI. That’s as true for our classic vermouths and sparkling wines as it is for our newest innovation, the fantastic MARTINI Non-Alcoholic Aperitivo range. We are ready to celebrate the 160th anniversary of this iconic brand in style!”
Find out more about the sustainability commitments of Bacardi and its vision to become the most environmentally responsible global spirits company at www.bacardilimited.com/good-spirited .
Always drink responsibly.
About MARTINI
One of the most iconic brands in the world, MARTINI® is the leading name in Italian winemaking and a purveyor of the highest quality aromatized and sparkling wines. The award- winning, vibrant and bittersweet taste of the MARTINI range is the result of secret blends of more than 40 botanicals sourced from the finest locations across the globe. First created in 1863 in Turin, Italy, the MARTINI portfolio today includes: MARTINI Fiero, MARTINI Riserva Speciale Rubino, Ambrato & Bitter, MARTINI Bianco, Rosato, Rosso & Extra Dry, MARTINI Non-Alcoholic Vibrante & Floreale, MARTINI Asti, Prosecco & Rosé Extra Dry. For more information, please visit www.martini.com .
MARTINI and the ball & bar logo are trademarks. MARTINI is part of the portfolio of Bacardi Limited, headquartered in Hamilton, Bermuda. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited.
About Bacardi
Bacardi Limited, the largest privately held spirits company in the world, produces and markets internationally recognized spirits and wines. The Bacardi Limited brand portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, GREY GOOSE® vodka, PATRÓN® tequila, DEWAR’S® Blended Scotch whisky, BOMBAY SAPPHIRE® gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including WILLIAM LAWSON’S® Scotch whisky, ST-GERMAIN® elderflower liqueur, and ERISTOFF® vodka. Founded 160 years ago in Santiago de Cuba, family-owned Bacardi Limited currently employs more than 8,000, operates production facilities in 10 countries, and sells its brands in more than 170 countries. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit www.bacardilimited.com or follow us on Twitter , LinkedIn or Instagram .
About Equalitas
Equalitas is an Italian-born sustainability initiative promoted by Federdoc. Federdoc is the Italian Confederation of Voluntary Consortia for the Protection of the Designations of the Italian Wines. In 2015, Federdoc began several initiatives in the Italian wine value chain including the promotion of one main, certifiable, sustainability standard for companies in the wine sector. Equalitas (the company) is a so called “standard owner”, and it has issued the SOPD Equalitas standard, a set of good practice requirements and sustainability indicators. Through an audit made by third party Certification Bodies, wineries can certify against SOPD Equalitas. Visit www.equalitas.it .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220705005231/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom